• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

    3/16/22 9:00:00 AM ET
    $ABT
    $BSGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ABT alert in real time by email

    Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer.

    Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories (NYSE:ABT). During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice President & General Manager when he led sales and customer relationship management activities in the United States across all cardiovascular product lines.   Mr. Sieckhaus's experience in building and leading high-performance teams, in addition to integrating multiple new and novel technologies and introducing them commercially, led to significant revenue growth for St. Jude Medical over his career. Most recently, Mr. Sieckhaus held the position of Vice President – Field Clinical Affairs for Abbott for the United States and CALA, where he created a world-class field clinical and monitoring team to support clinical trials across multiple business units within Abbott's Cardiovascular portfolio. Mr. Sieckhaus holds a Bachelor of Science degree in Biomedical Engineering from Johns Hopkins University.

    "I am very excited to join this team and look forward to building upon the foundation of the PURE EP™ system and its capabilities. Focusing in the area of electrophysiology by providing better solutions in identifying and treating complex arrhythmias for our clinical customers and patients will be extremely rewarding," commented Mr. Sieckhaus

    "We are pleased to welcome John to the team as we build toward a national rollout of our leading product, PURE EP ™. John's leadership experience in the electrophysiology space and his impressive track record in capturing and growing market share in the U.S.  is well-aligned with our mission to bring our signal processing technology to as many hospitals as possible in the coming years. John will join Gray Fleming in helping run and grow our business while attracting additional talent to the Company," commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

    The PURE EP™ is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, 75 physicians have completed more than 2150 patient cases with the PURE EP™ System.

    Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™  signals over conventional sources.

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.



    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    55 Greens Farms Road
    Westport, CT 06880
    [email protected]
    203-409-5444, x133
    
    

    Primary Logo

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT
    $BSGM

    CompanyDatePrice TargetRatingAnalyst
    Abbott Laboratories
    $ABT
    10/8/2024$130.00Outperform
    Oppenheimer
    Abbott Laboratories
    $ABT
    9/19/2024$131.00Overweight
    Piper Sandler
    Abbott Laboratories
    $ABT
    7/30/2024Buy → Hold
    Edward Jones
    Abbott Laboratories
    $ABT
    5/30/2024$121.00Buy
    Goldman
    Abbott Laboratories
    $ABT
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    Abbott Laboratories
    $ABT
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    Abbott Laboratories
    $ABT
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    Abbott Laboratories
    $ABT
    4/20/2023$107.00 → $103.00Underperform
    Wolfe Research
    More analyst ratings

    $ABT
    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioSig Technologies Inc.

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/14/24 3:31:45 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/13/24 4:55:58 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $BSGM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Labs downgraded by Edward Jones

      Edward Jones downgraded Abbott Labs from Buy to Hold

      7/30/24 6:16:11 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

      Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

      5/5/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ABT
    $BSGM
    Financials

    Live finance-specific insights

    See more
    • Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

      First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe

      4/16/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Hosts Conference Call for First-Quarter Earnings

      ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi

      3/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $BSGM
    Leadership Updates

    Live Leadership Updates

    See more
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

      Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

      5/5/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $ABT
    $BSGM
    SEC Filings

    See more
    • BioSig Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/5/25 9:17:41 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Abbott Laboratories filed SEC Form 8-K: Leadership Update

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      5/1/25 4:01:21 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abbott Laboratories

      10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

      4/30/25 4:14:32 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care